Kathleen Poston, MD, PhD, Stanford University Medical Center, Stanford, CA, discusses the latest updates in the field of Parkinson’s disease neuroimaging biomarkers. Dr Poston mentions the Parkinson’s Progression Markers Initiative (PPMI), an ongoing observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson’s disease progression. Additionally, Dr Poston describes the potential of MRI biomarkers to characterize disease processes in Parkinson’s disease and outlines some of the advantages of MRI-based imaging biomarkers, including costs and availability to patients. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).
